# Phase 1 Erlotinib and Dovitinib (TKI258) in Advanced Non-small Cell Lung Cancer (NSCLC)

> **NCT01515969** · PHASE1 · TERMINATED · sponsor: **Heather Wakelee** · enrollment: 9 (actual)

## Conditions studied

- Non-small Cell Lung Cancer (NSCLC), Recurrent
- Non-small Cell Lung Cancer (NSCLC), Stage IV

## Interventions

- **DRUG:** Erlotinib hydrochloride
- **DRUG:** Dovitinib lactate

## Key facts

- **NCT ID:** NCT01515969
- **Lead sponsor:** Heather Wakelee
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2012-07
- **Primary completion:** 2013-02
- **Final completion:** 2014-12
- **Target enrollment:** 9 (ACTUAL)
- **Why stopped:** Patient safety - Unacceptable toxicity
- **Last updated:** 2016-07-12

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01515969

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01515969, "Phase 1 Erlotinib and Dovitinib (TKI258) in Advanced Non-small Cell Lung Cancer (NSCLC)". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT01515969. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*